It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The APC/C-Cdh1 ubiquitin ligase complex drives proteosomal degradation of cell cycle regulators and other cellular proteins during the G1 phase of the cycle. The complex serves as an important modulator of the G1/S transition and prevents premature entry into S phase, genomic instability, and tumor development. Additionally, mounting evidence supports a role for this complex in cell differentiation, but its relevance in erythropoiesis has not been addressed so far. Here we show, using mouse models of Cdh1 deletion, that APC/C-Cdh1 activity is required for efficient terminal erythroid differentiation during fetal development as well as postnatally. Consistently, Cdh1 ablation leads to mild but persistent anemia from birth to adulthood. Interestingly, loss of Cdh1 seems to affect both, steady-state and stress erythropoiesis. Detailed analysis of Cdh1-deficient erythroid populations revealed accumulation of DNA damage in maturing erythroblasts and signs of delayed G2/M transition. Moreover, through direct assessment of replication dynamics in fetal liver cells, we uncovered slow fork movement and increased origin usage in the absence of Cdh1, strongly suggesting replicative stress to be the underlying cause of DNA lesions and cell cycle delays in erythroblasts devoid of Cdh1. In turn, these alterations would restrain full maturation of erythroblasts into reticulocytes and reduce the output of functional erythrocytes, leading to anemia. Our results further highlight the relevance of APC/C-Cdh1 activity for terminal differentiation and underscore the need for precise control of replication dynamics for efficient supply of red blood cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CSIC/Universidad de Salamanca, Instituto de Biología Funcional y Genómica (IBFG), Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817); CSIC/Universidad de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
2 CSIC/Universidad de Salamanca, Instituto de Biología Funcional y Genómica (IBFG), Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817); Adrestia Therapeutics, Cambridge, UK (GRID:grid.11762.33)
3 CSIC/Universidad de Salamanca, Instituto de Biología Funcional y Genómica (IBFG), Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
4 CSIC/Universidad de Salamanca, Instituto de Biología Funcional y Genómica (IBFG), Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817); Universidad Autónoma de Madrid/CSIC, Departamento de Biología Molecular, Instituto de Biología Molecular (IUBM) and Centro de Biología Molecular “Severo Ochoa”, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126)